Emma Dean1,2, Leila Khoja1,3, Andrew Clamp1,2, Gordon C Jayson1,2, Dilly Goonetilleke1,2, Alicia M Conway1, Jurjees Hasan1. 1. The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK. 2. Division of Molecular & Clinical Cancer Sciences, University of Manchester, Manchester, M13 9NT, UK. 3. AstraZeneca Ltd, Early Clinical Development, Melbourn Science Park, Melbourn, Hertfordshire, SG8 6HB, UK.
Abstract
AIM: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood. METHODS: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO. RESULTS: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01). CONCLUSION: The Manchester Bowel Obstruction Score may aide treatment stratification.
AIM: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood. METHODS: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO. RESULTS: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01). CONCLUSION: The Manchester Bowel Obstruction Score may aide treatment stratification.
Authors: Yeh Chen Lee; Nazlin Jivraj; Catherine O'Brien; Tanya Chawla; Eran Shlomovitz; Sarah Buchanan; Jenny Lau; Jennifer Croke; Johane P Allard; Preeti Dhar; Stephane Laframboise; Sarah E Ferguson; Neesha Dhani; Marcus Butler; Pamela Ng; Terri Stuart-McEwan; Pamela Savage; Lisa Tinker; Amit M Oza; Stephanie Lheureux Journal: Obstet Gynecol Int Date: 2018-05-17
Authors: Robert D Morgan; Sofia Stamatopoulou; Nerissa Mescallado; Geoff Saunders; Richard Welch; Claire Mitchell; Jurjees Hasan; Andrew R Clamp; Gordon C Jayson Journal: ESMO Open Date: 2019-03-21
Authors: Tejas Patil; Jose M Pacheco; Anastasios Dimou; William T Purcell; Candice Rossi; Paul A Bunn; Robert C Doebele; D Ross Camidge; Lisa Ferrigno Journal: Front Oncol Date: 2020-04-15 Impact factor: 5.738